the moderate tertiles had a substantial association with VTE for patients with all cancers and non-brain cancers [adjusted ORs: 1.84(P = 0.011) and 3.28(P = 0.033), respectively]. Hs-TnT levels inside the moderate tertiles was related with a decreased threat of VTE in comparison to the highest tertile as reference within the all cancer and non-brain cancer models.College of Epidemiology and Public Wellness, University of Ottawa,Ottawa, Canada; 2Department of Medicine, University of Ottawa, Ottawa, Canada; 3Ottawa Hospital Investigation Institute, Ottawa, Canada; 4University of Ottawa Heart Institute, Ottawa, CanadaTABLE 1 Descriptive Statistics Based on Venous Thromboembolism EventsVenous Thromboembolism (n = 477) Predictors Mean Age, years (SD) Sex ( ) Yes (n = 32) 62.59 (12.0) No (n = 445) 60.87 (15.0) P-valueMale Female17 (53.1 ) 15 (46.9 ) 23 (71.9 ) 9 (28.1 ) 27 (76.9 ) five (15.six ) four (12.5 ) eight (25.0 ) 0 (0 ) 5 (15.six ) 0 (0 ) 6 (18.eight ) 7 (21.9 ) 0 (0 ) two (6.two )179 (40.2 ) 266 (59.8 )0.Therapy ( )0.0087Control ApixabanAntiplatelet Use ( )213 (47.9 ) 232 (52.1 )0.No YesCancer ( )342 (76.9 ) 103 (23.2 )0.Brain Gynecologic Lung Lymphoma Myeloma Pancreas Stomach Breast Other18 (4.0 ) 126 (28.3 ) 46 (10.3 ) 116 (26.0 ) 14 (three.1 ) 51 (11.4 ) 28 (six.3 ) 16 (3.6 ) 31 (7.0 )804 of|ABSTRACTVenous Thromboembolism (n = 477) Predictors Median GDF-15, pg/mL (IQR) Median NT-ProBNP, pg/mL (IQR) Median hs-TnT, pg/mL (IQR) Yes (n = 32) 2352 (2726) 175 (179) 8.54 (13.08) No (n = 445) 1910 (2064) 111.80 (182.33) six.10 (7.28) P-value 0.2036 0.1045 0.TABLE two Logistic Regression Models Seeking at Associations among Biomarkers and VTEModel 1 (n = 477)Biomarker GDF-15 TertilesModel 2 (n = 455)P-value Model three (n = 134)P-value OR (95 CI)OR (95 CI)OR (95 CI)P-value Low (ref) (1415 pg/mL)0.87 (0.36.06) 0.747 1.62 (0.71.72) 0.253 1.41 (0.25.86) 0.Moderate (1415581 pg/ mL)1.66 (0.77.62) 0.199 3.16 (1.52.57) 0.002 4.27 (1.422.87) 0.010High (2581 pg/mL)NT-proBNP Tertiles Low (ref) (64.eight pg/mL)1.84 (1.15.95) 0.011 three.28 (1.10.76) 0.033 2.77 (0.0712.03) 0.Moderate (64.889.4 pg/ mL)1.67 (0.74.76) 0.220 three.22 (0.646.33) 0.High (189.four pg/mL)Hs-TnT Tertiles 0.53 (0.27.05) 0.069 0.63 (0.29.37) 0.10.45 (0.4540.80)0.0.93 (0.12.48)0.Low (4.4 pg/mL)0.45 (0.26.77) 0.004 0.47 (0.24.92) 0.028 0.15 (0.02.48) 0.Moderate (4.4 -8.91 pg/mL)High (ref) (eight.91 pg/mL) Conclusions: In this very first study to evaluate the predictive overall performance of GDF-15, proBNP and hs-TnT for VTE in individuals with cancer, greater tertile GDF-15 and NT-proBNP predicted increased VTE danger whereas larger hs-TnT predicted decreased VTE risk.ABSTRACT805 of|PB1091|Qualities and Outcomes of Patients on IL-8 Antagonist web concurrent Direct Oral HIV-1 Inhibitor Accession Anticoagulants and Targeted Anticancer Therapies TacDOAC Registry T.-F. Wang1; L. Baumann Kreuziger2; A. Leader3,4; G. Spectre3,four; M. Lim ; A. Gahagan ; R. Gangaraju ; K. Sanfilippo ; R. Mallick ; J. Zwicker ; M. Carrier1 eight 9 1 five 6 6Aims: We performed an international registry through the SSC of ISTH to evaluate bleeding and thrombotic outcomes in sufferers receiving concurrent DOACs and targeted anticancer therapies. Strategies: Sufferers receiving concurrent DOACs and selected targeted anticancer therapies have been integrated (largely retrospectively) and followed for six months immediately after the start out of concurrent use. Data such as patient and cancer traits, major bleeding, nonmajor bleeding events, venous or arterial thromboses were collected and analyzed. The main outcome was key bleeding by ISTH criteria. A
